Phase 4Completed

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS

Sponsor
Pfizer (Industry)
Enrollment
4,372 enrolled
Conditions
Arthritis, Rheumatoid
Interventions
tofacitinib; tofacitinib; adalimumab; etanercept
Ages
adults, older adults
Registry
NCT02092467, EUCTR2013-003177-99

Full record on ClinicalTrials.gov

From the registry

This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.

Primary outcomes

  • Incidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin Cancers (NMSC)
  • Incidence Rate of Adjudicated Major Adverse Cardiovascular Events (MACE)

History

  1. Results first posted

  2. Last registry update

  3. Primary completion

  4. Registered

  5. Started